Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo To Launch Private Label Mucinex, Prevacid, With An Eye On Lipitor

This article was originally published in The Tan Sheet

Executive Summary

Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.
Advertisement

Related Content

Perrigo Nutritional Dip Riles Analysts Amid Record Consumer Sales
Perrigo Nutritional Dip Riles Analysts Amid Record Consumer Sales
Perrigo OTCs, Nutritionals Underperform Despite Record Overall Revenue
J&J Consumer Recaptures Growth, Plans To Restore Most OTCs By Mid-2012
Perrigo's Zantac 150 Generic Marks First Approval From Remediated Plant
Perrigo Rogaine Foam ANDA May Help Extend Record Growth
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Abbott's Similac Recall Triggers Overflow Demand For Answers
Perrigo Grows Into Adjacent Infant Formula Category With PBM Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS105256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel